Cancer News and Research

Latest Cancer News and Research

Genoptix to participate 2010 UBS Global Life Sciences Conference

Genoptix, Inc., a specialized laboratory services provider, today announced the Company's participation at the 2010 UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, to be held September 20-22, 2010.

13 Sep 2010

Regis to kick off Clip for the Cure campaign to raise money, awareness for breast cancer research

In October, Regis Corporation, the global leader in the haircare industry, will kick off its annual Clip for the Cure, a month-long campaign to raise money and awareness for breast cancer research in support of National Breast Cancer Awareness Month. To date, the company's dedicated stylists and clients have raised more than $6.5 million for the cause.

13 Sep 2010

Geron, UCS collaborate to develop hESC-derived chondrocytes for cartilage damage, joint disease treatment

Geron Corporation today announced that the company has entered into a collaboration with University Campus Suffolk (UCS) in the U.K. to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease.

13 Sep 2010

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.

13 Sep 2010

Geron signs worldwide, exclusive license agreement with University of Edinburgh

Geron Corporation today announced that it has entered into a worldwide, exclusive license agreement with the University of Edinburgh covering technology that allows the efficient production of chondrocytes (cartilage forming cells) from human pluripotent stem cells.

13 Sep 2010

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has engaged the Numoda Corporation, a leading information, process and logistics management company, to oversee the Phase III clinical trial of DAVANAT and 5-FU compared with the standard of care in the treatment of patients with advanced, metastatic colorectal cancer.

13 Sep 2010

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase III trial for its JAK1 and JAK2 inhibitor, INCB18424 in patients with polycythemia vera (PV), a blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms (MPNs).

13 Sep 2010

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).

13 Sep 2010

PDL BioPharma announces conversion rate adjustment for Convertible Senior Notes due 2012

PDL BioPharma, Inc. today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) effective September 16, 2010 in connection with the special dividend to be paid on October 1, 2010 to all stockholders who own shares of PDL on September 15, 2010, the record date.

13 Sep 2010

Genes behind aggregation of arsenic in plants

In many countries arsenic in food is a major problem. But researchers at the University of Skövde in Sweden have now identified two genes that may play a crucial role in how arsenic is stored in plants.

13 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Genzyme Corporation enters into asset purchase agreement with LabCorp

Genzyme Corporation today announced that it has entered into an asset purchase agreement under which Laboratory Corporation of America Holdings (LabCorp) will acquire Genzyme Genetics for $925 million in cash.

13 Sep 2010

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

13 Sep 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.

13 Sep 2010

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.

13 Sep 2010

Leukemia survivor to meet donor of bone marrow transplant

Ann Marie Del Fiacco, a 38-year-old Berwyn mother of two, owes her life to a stranger who volunteered to be a donor for her life-saving bone marrow transplant.

13 Sep 2010

Researchers investigate human reovirus with chemotherapy for ovarian cancer

Researchers are now investigating whether the human reovirus, when prescribed along with chemotherapy, will provide a desperately needed "one-two punch" against ovarian cancer.

13 Sep 2010

Health risk assessments

At various points in our lives, we're curious about our health risks, wondering about our susceptibility for everything from high cholesterol to a deadly inherited disease. We might want to learn more about our risks when we reach a certain age or experience a bout of bad health; when we hear about a friend or co-worker coping with a dreaded illness; or read the latest headlines about disease research.

13 Sep 2010

Six California-based institutions collaborate to guide CDU

Six California-based institutions specializing in health, hospital, university and nonprofit health announced today the formation of a new and unprecedented collaboration effort to rescue, restructure, reinvigorate and guide Charles R. Drew University of Medicine and Science (CDU) towards a new, resurgent and financially viable future.

13 Sep 2010

CAP forges collaboration with CAP-ACP and RCPA for development of cancer protocols

The College of American Pathologists (CAP) recently signed Memoranda of Understanding (MOUs) with the Canadian Association of Pathologists (CAP-ACP) and the Royal College of Pathologists Australasia (RCPA), forging a collaboration in the development of cancer datasets, also called protocols. The CAP Cancer Protocols are designed as a guideline for definitive cancer reporting.

13 Sep 2010

Cancer News and Research

Latest Cancer News and Research

Genoptix to participate 2010 UBS Global Life Sciences Conference

Regis to kick off Clip for the Cure campaign to raise money, awareness for breast cancer research

Geron, UCS collaborate to develop hESC-derived chondrocytes for cartilage damage, joint disease treatment

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Geron signs worldwide, exclusive license agreement with University of Edinburgh

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

PDL BioPharma announces conversion rate adjustment for Convertible Senior Notes due 2012

Genes behind aggregation of arsenic in plants

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Genzyme Corporation enters into asset purchase agreement with LabCorp

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

Leukemia survivor to meet donor of bone marrow transplant

Researchers investigate human reovirus with chemotherapy for ovarian cancer

Health risk assessments

Six California-based institutions collaborate to guide CDU

CAP forges collaboration with CAP-ACP and RCPA for development of cancer protocols

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in